---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-105904"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:38:54.648303+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rhythm Q3 IMCIVREE revenue $51.3M; net loss -$0.82/sh; PDUFA Dec 20

## Summary
- Q3 2025 IMCIVREE revenue $51.3M (+6% seq, +54% YoY); US $38.2M (+19% seq).
- Net loss ($54.3M) or ($0.82)/share vs ($45.0M) or ($0.73)/share a year ago.
- Cash and investments $416.1M at Sep 30, 2025, up from $320.6M at Dec 31, 2024.
- Updated FY2025 non-GAAP operating expense guidance $295M-$315M excluding stock-based compensation.
- PDUFA date Dec 20, 2025 for setmelanotide sNDA in acquired hypothalamic obesity; Phase 2 PWS data Q4 2025.

## SEC filing metadata
- accession: 0001104659-25-105904
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000110465925105904/0001104659-25-105904-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000110465925105904/rytm-20251104x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-105904
- JSON: https://secwatch.observer/filing/0001104659-25-105904.json
- Plain text: https://secwatch.observer/filing/0001104659-25-105904.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.